Download Full Text (3.2 MB)


in women. Invasive breast cancer results in approximately 28% of all cancers diagnosed in the United States. This year, an estimated 276,480 women in the United States will be diagnosed with invasive breast cancer. It is estimated that 42,690 deaths (42,170 women and 520 men) from breast cancer will occur this year. As a result, there is an urgent need for more effective and less toxic treatments for this devastating disease. Many anticancer drugs used to clinically treat cancers mediate tumor cell death through the induction of apoptosis. Cancer cells, however, often acquire resistance following prolonged exposure to clinical chemotherapeutic drugs. Consequently, molecular pathways involved in tumor cell proliferation and apoptosis have become potential targets for pharmacological intervention. Our group has targeted ceramide metabolism as a potential pharmacological intervention in the treatment of breast cancer. One novel approach is to synthesize ceramide analogs with greater efficacy and specificity than endogenous ceramides. Multiple families of ceramide analogs have been synthesized and evaluated in our previous studies leading to the current structure-activity relationship information. Analog 315 has been identified as the most promising analog. Analog 315 has proven to be less toxic and more effective than several previously studied ceramide analogs and will be used as a lead compound to synthesize additional ceramide analogs.

Publication Date

Summer 2020


Xavier University of Louisiana


New Orleans


Ceramide Analog 315, Inhibitory Effects, Breast Cancer, Tumor Growth



Ceramide Analog 315 and its Inhibitory Effects on Breast Cancer Tumor Growth